TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8554937
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg 8‐MOP
Study: 8554937
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg 8‐MOP
Study: 8554937
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg 8‐MOP
Study: 8554937
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg 8‐MOP added to 300 ml platelet concentrate
Study: 8554937
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 7.5 mg 8‐MOP over 60 min
Study: 8554937
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of 8‐MOP
Study: 1838256
Drug: 2% ketoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% ketoconazole cream (Nizoral)
Study: 1838256
Drug: Bland cream
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bland cream (control)
Study: 6117584
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (holiday group)
Study: 6117584
Drug: Regular medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular medication (control group)
Study: 29550235
Drug: Early Limited
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early Limited Formula (ELF), 10 mL of formula after each breastfeeding until copious maternal milk production
Study: 26349843
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (25 mg/ml)
Study: 18236463
Drug: High-dose beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose beta interferon-1a
Study: 15265847
Drug: Pravastatin, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin, 20 to 40 mg/d
Study: 3470953
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel (Prepidil)
Study: 3470953
Drug: Artificial rupture
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial rupture of membranes combined with intravenous oxytocin
Study: 20163739
Drug: Physiotherapy program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy program including exercise and manual therapy (individual sessions once a week for 10 weeks and daily home exercises)
Study: 20163739
Drug: Physiotherapy program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy program including exercise and manual therapy
Study: 1437342
Drug: Bovine surfactant
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bovine surfactant (50 mg/kg BW)
Study: 3885671
Drug: Hydroxyprogesterone caproate
Normalized name: Hydroxyprogesterone Caproate
DrugBank: Hydroxyprogesterone caproate (DB06789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxyprogesterone caproate (5000 mg i.m. as a loading dose followed by 1000 mg every 2 weeks for one year)
Study: 29738817
Drug: Antimicrobial photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial photodynamic therapy (aPDT) with open flap debridement (OFD)
Study: 19794988
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg intravenous ephedrine
Study: 11465585
Drug: BIS-guided, model-based,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS-guided, model-based, closed-loop system for propofol administration
Study: 11465585
Drug: Manual control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual control of propofol administration using classical hemodynamic signs
Study: 9622403
Drug: 30-minute music
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-minute music therapy intervention
Study: 7878692
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg orally three times a day for 6 days
Study: 2458438
Drug: Higher-dose chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose chemotherapy (600 mg/m2 cyclophosphamide and fluorouracil, 40 mg/m2 methotrexate)
Study: 2458438
Drug: Lower-dose chemotherapy
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose chemotherapy (300 mg/m2 cyclophosphamide and fluorouracil, 20 mg/m2 methotrexate)
Study: 2458438
Drug: Higher-dose chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose chemotherapy
Study: 2458438
Drug: Lower-dose chemotherapy
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose chemotherapy
Study: 2458438
Drug: Crossover from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover from lower-dose to higher-dose chemotherapy
Study: 29643011
Drug: Dolutegravir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir (50 mg oral once a day for 56 days)
Study: 29643011
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral once a day for 56 days)
Study: 25851628
Drug: trastuzumab and
Normalized name: pertuzumab and trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: trastuzumab and lapatinib combination
Study: 24180295
Drug: Structured and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured and repeated multidisciplinary medication review supported by education and continuous evaluation.
Study: 20972646
Drug: Standard protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard protein supplement; 20% of estimated nitrogen requirements for 14 days
Study: 12354133
Drug: L‐T4 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐T4 + I (iodized salt)
Study: 12354133
Drug: L‐T4 alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐T4 alone
Study: 8587426
Drug: ET-1 (nonselective
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET-1 (nonselective agonist at ETA and ETB receptors)
Study: 8587426
Drug: ET-3 (ETB
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET-3 (ETB receptor agonist)
Study: 8587426
Drug: Sarafotoxin S6c
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarafotoxin S6c (ETB receptor agonist)
Study: 333761
Drug: Live mumps
Normalized name: mumps virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live mumps vaccine from L-3 strain, single injection of 10(4)HAdU50 of mumps virus.
Study: 333761
Drug: Live mumps
Normalized name: mumps virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live mumps vaccine from L-3 strain.
Study: 12854503
Drug: Low-dose radiation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiation therapy (10 fractions of 2 Gy external beam)
Study: 1682683
Drug: Active antihypertensive
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active antihypertensive therapy (three beta-blockers and one diuretic)
Study: 7007473
Drug: Hydroxyzine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 150 mg/day
Study: 7007473
Drug: Chlorpheniramine 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine 24 mg/day
Study: 31362969
Drug: Antibiotic distribution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic distribution
Study: 29448858
Drug: 3ABVD +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3ABVD + involved-field (IF) low-dose (LD) irradiation (20 Gy) for GR1 patients with mediastinal mass or partial response after chemotherapy.
Study: 24374068
Drug: Micronutrient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient treatment for 8 weeks
Study: 21162840
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg CHO hepatitis B vaccine
Study: 21162840
Drug: 20 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg CHO hepatitis B vaccine
Study: 12351591
Drug: Intensified CDE
Normalized name: 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
DrugBank: Ellagic acid (DB08846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified CDE (cyclophosphamide 1,250 mg/m(2), doxorubicin 55 mg/m(2), etoposide 125 mg/m(2) with G-CSF 5 micro g/kg/d)
Study: 12351591
Drug: Standard CDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard CDE (cyclophosphamide 1,000 mg/m(2), doxorubicin 45 mg/m(2), etoposide 100 mg/m(2))
Study: 9690802
Drug: Steroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid therapy (specific dosage and duration not mentioned)
Study: 7710467
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel (0.5 mg)
Study: 2511611
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of phenoxymethylpenicillin suspension
Study: 2511611
Drug: Standard formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formulation of phenoxymethylpenicillin suspension
Study: 25954938
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) for 12 weeks
Study: 25954938
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 to 20 mg) for 12 weeks
Study: 22900665
Drug: Traditional oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional oral healthcare information (Control)
Study: 21810897
Drug: Captopril and
Normalized name: captopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril and atenolol as monotherapy
Study: 11282268
Drug: Intravenous pefloxacin
Normalized name: pefloxacin
DrugBank: Pefloxacin (DB00487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pefloxacin (800 mg)
Study: 8292723
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of vitamin K1 orally in addition to the usual warfarin dose (group B)
Study: 8292723
Drug: Discontinued warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued warfarin for one day (group A)
Study: 8292723
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups continued with their usual dose of warfarin after day 1
Study: 22446297
Drug: T-614 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-614 group 2 (25mg twice daily)
Study: 22446297
Drug: MTX group
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX group (10 mg/week for the first 4 weeks and 15 mg/week for the subsequent 20 weeks)
Study: 22446297
Drug: T-614 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-614 (50 μg/ml)
Study: 22446297
Drug: T-614 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-614 (5 μg/ml or more)
Study: 22446297
Drug: T-614 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-614 treatment
Study: 20173715
Drug: Short prophylactic
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short prophylactic therapy (2 grams of amoxicillin 1 hour before the procedure and 1 gram 6 hours after surgery)
Study: 20173715
Drug: Long postoperative
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long postoperative regimen (1 gram of amoxicillin 6 hours after surgery followed by 1 gram every 8 hours for 4 days)
Study: 14664688
Drug: Fixed model
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed model approach for evaluating therapy studies
Study: 10641419
Drug: Comprehensive periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comprehensive periodontal treatment with emphasis on oral hygiene
Study: 10641419
Drug: Nifedipine administration
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine administration
Study: 8889288
Drug: D-cycloserine 5
Normalized name: D-(+)-cycloserine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine 5 mg p.o. b.i.d. + molindone 150 mg p.o. q.d.
Study: 8889288
Drug: D-cycloserine 15
Normalized name: D-(+)-cycloserine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine 15 mg p.o. b.i.d. + molindone 150 mg p.o. q.d.
Study: 8889288
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + molindone 150 mg p.o. q.d.
Study: 6362553
Drug: Amoxicillin‐clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin‐clavulanic acid (A‐C) for 10 days
Study: 23972694
Drug: GXR administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: GXR administered in the morning (1-4 mg/d)
Study: 23972694
Drug: GXR administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: GXR administered in the evening (1-4 mg/d)
Study: 27550184
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice daily
Study: 16761155
Drug: Day hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day hospital nurses handling antineoplastic drugs
Study: 12409635
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy (n = 810)
Study: 9836156
Drug: Natural drying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural drying of the umbilical site without special treatment
Study: 2910758
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg twice daily for 1 week)
Study: 2910758
Drug: Cimetidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (50 mg/kg body wt) in rats
Study: 30360748
Drug: Oral Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Levofloxacin (TAVANEX), 750 mg, once daily for five days
Study: 30360748
Drug: Parenteral Ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral Ceftriaxone 1gr BD plus oral Azithromycin (250 mg, once daily) for seven to ten days
Study: 18824931
Drug: Aspirin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (10 mg x kg(‐1))
Study: 14707397
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 750 mg/day for 6 months
Study: 7676787
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with 1.0 mg alfentanil
Study: 2305332
Drug: Pivampicillin (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin (700 mg twice daily for 9 days)
Study: 2305332
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg on the first day, then 100 mg daily plus one placebo tablet for 9 days)
Study: 24457604
Drug: UPA 5
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: UPA 5 mg
Study: 24457604
Drug: UPA 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: UPA 10 mg
Study: 22980429
Drug: 3% acetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% acetic acid gel
Study: 17263884
Drug: No IL-2
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No IL-2 therapy (Control)
Study: 1752914
Drug: liquid-filled soft
Normalized name: Foster & Thrive Ibuprofen 200mg Liquid-Filled Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: liquid-filled soft gelatin capsules (TL)
Study: 11916761
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg FeSO4 twice daily for 6 weeks
Study: 11916761
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 6 weeks
Study: 9864077
Drug: Lithium (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (serum drug level 0.6+/‐0.1 mmol/L)
Study: 9864077
Drug: Carbamazepine (serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (serum drug level 6.1+/‐1.3 microg/mL)
Study: 8471984
Drug: Cyclophosphamide with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide with low dose alpha-interferon (IFN)
Study: 25525163
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement (vitamin C, E, zinc, lutein/zeaxanthin, selenium, taurine, Aronia extract, omega-3 free fatty acids)
Study: 22849546
Drug: Conventional triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional triple therapy (10 days of lansoprazole, amoxicillin, and clarithromycin)
Study: 17432784
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg once daily for 3 days after extraction
Study: 17432784
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline 3 times daily from 24 hours after extraction for 7 days
Study: 11870500
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg day(-1) orally) + 5-fluorouracil (200 mg day(-1))
Study: 7263877
Drug: Rational-emotive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational-emotive therapy (RET)
Study: 28183585
Drug: Longitudinal view
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longitudinal view (group L)
Study: 24132814
Drug: SOMA (somatostatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOMA (somatostatin 300 μg/hour and heparin 70 mIE/kg/min)
Study: 24132814
Drug: SALINE (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: SALINE (saline infusion)
Study: 20682548
Drug: Short-term gemcitabine
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term gemcitabine and paclitaxel chemotherapy (arm A)
Study: 20682548
Drug: Prolonged gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged gemcitabine and paclitaxel chemotherapy (arm B)
Study: 19330493
Drug: Fixed-dose manidipine/delapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose manidipine/delapril
Study: 17570342
Drug: Single session
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single session of behavioral treatment involving self-exposure instructions
Study: 15297125
Drug: Topical nonsteroid
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nonsteroid anti-inflammatory drugs
Study: 15297125
Drug: Acupuncture, extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture, extracorporeal shock wave therapy, manipulation, orthoses, low-energy laser, glycosaminoglycan polysulfate injection, botulinum toxin injection, topical nitric oxide application
Study: 8838609
Drug: Fenfluramine (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (20, 40 mg)
Study: 891280
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of fenoterol hydrobromide
Study: 891280
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg of fenoterol hydrobromide
Study: 891280
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of fenoterol hydrobromide
Study: 891280
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg of ephedrine
Study: 24065259
Drug: Contrast-enhanced sonography
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced sonography with intravenous administration of 2.4 mL of sulfur hexafluoride
Study: 21332811
Drug: Anti-cellulite cream
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-cellulite cream
Study: 15220015
Drug: Amlodipine camsylate
Normalized name: amlodipine camsylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine camsylate (newly developed formulation)
Study: 15220015
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate (conventional formulation)
Study: 19463517
Drug: Ezetimibe 5
Normalized name: EZETIMIBE 5MG/ROSUVASTATIN 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 5 mg
Study: 11558859
Drug: Ezetimibe 5
Normalized name: EZETIMIBE 5MG/ROSUVASTATIN 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 5 mg and 10 mg
Study: 11558859
Drug: Ezetimibe (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (all doses)
Study: 9604858
Drug: Untreated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated coffee (150 ml)
Study: 9604858
Drug: Specially treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specially treated coffee (150 ml)
Study: 29667557
Drug: M2000 (β-D-mannuronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: M2000 (β-D-mannuronic Acid) 500 mg orally twice daily for 12 weeks
Study: 28513786
Drug: Atraumatic Restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic Restorative Treatment (ART) sealants
Study: 25646254
Drug: Daily 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 4% chlorhexidine umbilical cord wash
Study: 23617089
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate (CP) 1.2%‐benzoyl peroxide (BPO) 2.5% gel
Study: 9365092
Drug: Intramuscular methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular methylprednisolone
Study: 9365092
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (oral prednisolone and intramuscular methylprednisolone)
Study: 9365092
Drug: Corticosteroid tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroid tapering
Study: 1471663
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (6 gm intravenous bolus)
Study: 4059295
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g triletide
Study: 4059296
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g triletide
Study: 4059295
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g triletide
Study: 31096724
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) treatment